Open Trials
|
|
|
Ovar |
|
|
AGO-OVAR 2.29Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer - a randomized Phase III trial
|
Download |
|
AGO-OVAR 2.31 / OReOA Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)
|
Download |
|
AGO-OVAR 2.32Trabectedin/PLD versus continuation of platinum-based chemotherapy in patients with disease stabilization and no symptom benefit under platinum-based chemotherapy for recurrent ovarian cancer
|
Download |
|
AGO-OVAR 2.33 / ANITAA phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months
|
Download |
|
Ovar / Endometrium / Cervix |
|
|
AtTEnd - Atezolizumab in Endometrial cancerPhase III double-blind randomized placebo controlled trial of Atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer
|
DownloadAtTEnd German Synopsis>> |
|
AGO-ZX 3 / BEATccA Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
|
DownloadBEATcc German Synopsis>> |
|
|
|
||
|
|
||
Clinical trials in surgical settings |
|
|
AGO-OVAR OP.6 ECLATPelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence. A multicenter, prospective randomized controlled trial
|
Download |
|
|
|
|
|
|
|
||
|
|
|
|